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2007-2011, with a 2-year history and a 3-year follow-up censored at the end of 2012, 
was designed in the EGB, a 1/97 random sample of the French national healthcare 
claims and hospitalization database. AF population was defined as patients with full 
coverage for AF, hospitalization or probabilistic AF information in the database, and 
without other probable cause of VKA prescription. NVAF population was defined as 
patients of the AF population without valvular disease history. Outcomes were the 
first hospitalization for bleeding, arterial thrombotic event (ATE), acute coronary 
syndrome (ACS), and death. Incidence rate of outcomes was estimated during VKA 
exposure. Results: Among 8,894 patients identified, 3,345 were classified in the 
AF population (3,977 person-years (PY)). Half were male (52%) with a mean age of 75 
years, 87% had a CHA2DS2-VASc score ≥ 2, and 12% a HAS-BLED score > 3. The inci-
dence rate of bleeding was 28 patients (95%CI [23-34]) for 1,000 PY exposed to VKA, 
including 6 [3-8] cerebral, 10 [7-13] digestive, and 14 [10-17] other bleeds. Incidence 
rates were 16 [12-20] for ACS, 15 [11-18] for ATE, and 38 [32-44] deaths for 1 000 PY 
exposed to VKA. Patient characteristics and incidence rates were very close for the 
2 818 patients with NVAF population criteria (3,367 PY). For this last population, 
incidence rates were 28 [22-34] for bleeding, 16 [12-20] for ACS, 15 [11-19] for ATE, and 
35 [29-41] deaths for 1 000 PY exposed to VKA. ConClusions: This study provides 
background reference for bleeding, ischemic events, and deaths before introduc-
tion of DOAC for NVAF with quite same frequency for AF and NVAF populations.
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objeCtives: Genetic factors have a great impact on the therapeutic dose of warfarin, 
a commonly prescribed anticoagulant. We still don’t consider them when prescrib-
ing warfarin, despite the high incidence of major and minor gastrointestinal (GI) 
bleeds. We evaluated the potential differential impact of warfarin-related GI bleeds 
risk factors according to the partient’s genetic profile. Methods: This study is based 
on a prospective cohort of new warfarin-users whose objectives were to assess the 
genetic, clinical and environmental risks associated with the effectiveness and safety 
of warfarin. Data was collected on 1069 patients who began the treatment between 
May 2010 and July 2013. Patients were followed-up each three months up to a year. 
The outcomes were minor and major GI bleeds. We used a multivariate Cox regres-
sion analysis. Results: Mean age was 70.8, 61.8% of patients were men, 68.4% had 
a history of hypertension and 60.8% of dyslipidemia and 76.4% had atrial fibrillation 
as a primary indication for warfarin. Overall, 4.8% of patients reported ≥ 1 minor GI 
bleed and 1.6% reported ≥ 1 major GI bleed. Patients with ≥ 1 polymorphism on both 
the CYP2C9 and the VKORC1 were significantly more at risk of having a major GI bleed 
(HR 10.72; p= 0.023). Patients with a history of MI or angina were at risk of having both 
minor and major GI bleeds (HR= 1.73 and HR= 2.63; p< 0.05). The impact of MI and 
angina disappeared for patients with no SNP on the CYP2C9 gene but was higher for 
patients with ≥ 1 SNP (HR= 2.44 and HR= 5.26, p< 0.05). ConClusions: Our results 
suggest an interaction between MI or angina history and the occurrence of major 
and minor GI bleeds, especially in patients with ≥ 1 polymorphism on the CYP2C9 
gene. Further analysis including concomitant drug use would help clarify clinical 
guidelines for this population and underlie the potential benefit of genetic testings.
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objeCtives: Heart failure (HF) affects 1.6 million people in Brazil. About 30%-40% 
progress to death in a year. This study aims to report 1-year retrospective analyses of 
hospital readmissions and mortality patterns associated to HF or all-other causes (OC) 
in a Brazilian cohort of patients with HF. Methods: Brazilian Hospital Information 
System (SIH/SUS) database was used to collect hospital readmissions and mortality 
data associated to HF or OC, according to ICD-10 codes (I50.0 and I50.9, and “others”, 
respectively). Patients were followed during 1 year (January-December 2014, regard-
less the entry data). Eligible criteria included patients with one previous HF hospital 
admission. Results: A cohort of 21,015 patients was considered eligible. No HF or OC 
hospital readmissions were observed for 13,050 (62%) and 5,241 (25%) patients, respec-
tively. For HF, 1, 2, 3, 4, and 5 re-hospitalizations were observed for 6,053, 1,255, 395, 152, 
and 59 patients. One patient required ten re-hospitalizations and the same occurred 
for 12 and 15 hospital readmissions. Therefore, about 38%, 9%, 3% and 1% of all 
patients had 1, 2, 3 or 4 hospital readmissions at least. OC readmissions showed higher 
number of patients for each amount of hospitalizations (11,046, 2,965, 989, 415, and 
184 for 1, 2, 3, 4, and 5, respectively). Seven patients required ten re-hospitalizations 
and 1 required 19. Compared to HF, OC showed approximately twice of all patients 
with 1 hospital readmission at least (75%). Mortality rate was 19.23%, 702 (3.34%) due 
to HF and 2,632 (12.52%) due to OC. ConClusions: The number of patients requiring 
hospitals readmissions for HF remain significant, despite available treatment options 
in Brazilian Public Healthcare System. OC results showed higher numbers, however, 
for this analysis all-other hospitalizations causes were included (except HF) indicat-
ing a high presence of comorbidities among this population and/or a misregistration 
at hospitalization time.
PCV48
heart faIlure In a health area of madrId, sPaIn. desCrIPtIon and 
manaGement from eleCtronIC medICal reCords
Parrondo J1, Sarria A2
1University of Alcalá, Coslada - Madrid, Spain, 2Agencia de Evaluación de Tecnologías Sanitarias - 
Instituto Carlos III, Madrid, Spain
inadequate control of LDL-C levels, despite being adherent to treatment Methods: 
An observational retrospective cohort analysis based on five Local Health Units 
administrative databases was conducted, for a total number of 1.2 Million benefi-
ciaries involved. Patients with at least one LDL-C measurement between January 
1, 2011 and December 31, 2012 were included. Patients were characterized back 12 
months to assess appropriateness and adherence to statin treatment Results: 
Among patients with LDL-C determination (1’218 patients), 578 (47%) and 640 (53%) 
displayed LDL-C under control and out of control, respectively. Among patients with 
uncontrolled LDL-C, 74 (12%) and 566 (88%) were not treated and treated with statins, 
respectively. Among patients with statins treatment, 188 (33%) and 378 (67%) were 
treated with low and high efficacy statins, respectively. Finally, among patients 
treated with high efficacy statins, 225 (60%) and 153 (40%) were non-adherent and 
adherent to high efficacy statin treatment, respectively. LDL-C uncontrolled high 
efficacy adherent patients showed different distances from their lipid target: 28% 
were less than 10% distant, 28.4% were 10-19% distant, 10.5% were 20-29% distant, 
11.1% were 30-39% distant and 24.8% were more than 40% distant ConClusions: 
These results are topical, as new monoclonal antibodies - PCSK9 inhibitors - are 
being marketed to address the residual unmet need in cholesterol statin-manage-
ment of dyslipidaemia for uncontrolled patients. By projecting study percentages to 
the Italian population, the number of LDL-C patients who are uncontrolled, despite 
being adherent to a high efficacy statin, would be around 17’825
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objeCtives: To identify the characteristics and assess the treatment of patients 
diagnosed with ischemic stroke. It was also performed to compare the manage-
ment of ischaemic stroke between current practice with the recommended guide-
line. Methods: Retrospective reviews of the medical records of patients who were 
diagnosed with ischemic stroke at the medical record’s office in a teaching hospital 
from January 1, 2013 to December 31, 2013. Patients’ medication for the treatment of 
stroke at discharge were reviewed and identified. Results: A total of 198 patients 
were diagnosed with ischemic stroke. This was found to be higher in men 104 (52.5%). 
In this study of 198 patients, 108 (54.5%) patients were diagnosed with newly onset 
of stroke and 28 (14.1%) patients were diagnosed with recurrent stroke. The major 
co-morbidities identified were the combination of hypertension and diabetis mel-
litus and hypertension alone, which were seen in 45 (22.7%) patients and 39 (19.7%) 
patients respectively. Aspirin and statin were the most commonly prescribed agent, 
which were 170 (85.9%) and 182 (91.9%) respectively. ConClusions: Majority of our 
patients are male, Malay and in the age range of 50-59. These patients had underly-
ing hypertension and diabetes upon their diagnosis of ischemic stroke. Aspirin and 
statin were mostly prescribed and widely used to treat ischaemic stroke. The current 
guidelines appear to have some influence on the current practice of the management 
of ischemic stroke.
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objeCtives: Elevated serum cholesterol levels are a well-known cause of car-
diovascular events. The objectives of this study were: to review the epidemiology 
of hypercholesterolemia in Spain; to detail the proportion of diagnosed patients 
undergoing pharmacological treatment (PhT); the degree of attained lipid con-
trol, and associated medical costs. Methods: A systematic literature review was 
carried out using Medline (pubmed) and Spanish databases as Medes and Biblioteca 
Virtual de la Salud. Manuscripts containing information on heterozygous familial hyper-
cholesterolemia (HeFH); hypercholesterolemia in primary prevention (PP) (diabetes mel-
litus or SCORE risk > 5) or secondary prevention (SP), published between January 2010 
and October 2014, were included. Results: Of the 1,947 published references initially 
retrieved, a full text review was done on 264 manuscripts and 120 were finally included. 
Prevalence of hypercholesterolemia ranged from 50%-84% in diabetics, 30%-60% in 
patients with high cardiovascular risk, 64%-74% with chronic coronary heart disease, 
33%-97% in acute coronary syndromes, 40%-70% in stroke patients, and 60%-80% in 
those with peripheral artery disease. Despite the finding that 30%-90% of patients were 
on pharmacological treatment, lipid control was found only in 15%-65% of cases in pri-
mary prevention and in 15%-56% of patients in secondary prevention. Among those with 
HeFH 95%-100% were treated but less than 16% achieved LDL-c target. ConClusions: 
An elevated prevalence of hypercholesterolemia can be seen in targeted groups at higher 
cardiovascular risk. Although most patients are receiving pharmacological treatment, 
rates of control continue to be low, both in primary and secondary prevention.
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objeCtives: To assess real-life outcomes in new Vitamin K antagonists (VKA) users 
for atrial fibrillation (AF), before introduction of direct oral anticoagulants (DOAC) 
for non-valvular AF (NVAF). Methods: Cohort study of new VKA users between 
